EUVIMEDEUVIMED entdecken
Crossref

Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma

Fanyuan Zeng, Hanwen Zhang, Shuhua Wang, Tenzin Passang, Yiwen Li, Christopher R Funk, Sarah Wyman, Colin B O'Leary, Aseala I Abousaud, Yuan Liu, Manali Rupji, Kavita M Dhodapkar und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Fanyuan Zeng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA; Xiangya School of Medic…. Hauptthemen laut MEDLINE: Cytokines, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Chemokines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for large B-cell lymphoma (LBCL); however, durable complete responses are achieved in only 30% to 40% of patients. Additionally, CAR-T therapy is frequently associated with significant toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). PATIENTS AND METHODS: We explored the translational potential of cytokines and chemokines as predictive biomarkers for CAR-T outcomes by analyzing 47 plasma cytokines/chemokines in serial blood samples from 24 LBCL patients undergoing CAR-T therapy. Blood samples were collected at multiple times: prelymphodepletion, day of CAR-T infusion (Day 0), and post-infusion. We investigated the association between cytokine levels and key clinical outcomes using machine learning models, including treatment response at 3 months, CRS, and ICANS. RESULTS: Higher day 0 IL-7, day 7 IL-21, and day 0 CCL8 levels correlated with improved remission rates. Conversely, elevated CRS risk was linked to higher day 0 CCL17 and day 3 CCL13, IL-6, and IFN-γ levels. ICANS development was associated with increased day 0 TGF-β1, and day 3 IL-5 and IL-7 levels, while lower day 0 CCL19 and day 3 VIP levels were inversely related to ICANS risk. Additionally, patients who received higher-intensity lymphodepletion had elevated day 0 CCL2 and IL-15 levels. CONCLUSION: These findings highlight the role of plasma cytokines and chemokines as biomarkers for predicting both the therapeutic efficacy and toxicity of CART, with the potential to guide more personalized, safer, and effective immunotherapies for B cell lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseChemokinesAntigens, CD19HumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeReceptors, Chimeric Antigen

Stichwörter der Autor:innen

CART T cellsChemokinesCytokine Release SyndromeCytokinesMachine learning

Substanzen

CytokinesChemokinesAntigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA; Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA; Department of Hematology and Medical Oncology, The University of Texas Southwestern Medical C…
  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA.
  • Department of Hematology and Medical Oncology, Children's Healthcare of Atlanta / Emory University, Atlanta, GA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA. Electronic address: ewaller@emory.edu.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA. Electronic address: jkoff@emory.edu.

Zitieren

APA

Zeng, F., Zhang, H., Wang, S., Passang, T., Li, Y., Funk, C. R., Wyman, S., O'Leary, C. B., Abousaud, A. I., Liu, Y., Rupji, M., Dhodapkar, K. M., Waller, E. K., & Koff, J. L. (2025). Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.02.009

Vancouver

Zeng F, Zhang H, Wang S, Passang T, Li Y, Funk CR, et al. Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.02.009

BibTeX
@article{Zeng2025,
  author = {Zeng, Fanyuan and Zhang, Hanwen and Wang, Shuhua and Passang, Tenzin and Li, Yiwen and Funk, Christopher R and Wyman, Sarah and O'Leary, Colin B and Abousaud, Aseala I and Liu, Yuan and Rupji, Manali and Dhodapkar, Kavita M and Waller, Edmund K and Koff, Jean L},
  title = {Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.02.009}
}
Kostenlos starten →